Objective
In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerging data now indicates that bvz fails to produce an enduring clinical response in a high proportion of patients. Delivery of the drug as part of a combination treatment regimen in mCRC elicits transitory improvements in the form of tumour stasis or shrinkage. Inevitably however, the tumours begin to re-grow and the disease progresses. It is now universally agreed that the future use of bvz in mCRC (and other cancers) is likely to be greatly influenced by the availability of predictive biomarkers to allow selection of patients who will attain the greatest benefit. The ANGIOPREDICT paradigm relies on a modular platform for the integrated discovery and validation of predictive pharmacogenomic biomarkers for combination bvz therapy in mCRC. Through initiation of a multi-centre clinical trial, early discovery findings will be validated for markers of Intrinsic Resistance to therapy. Parallel optimization of companion in vitro diagnostic tests (IVDs) through exploitation of proven SME development and validation strategies will ensure a cross-sectoral benefit to the cancer patient, prescribing physician and more broadly, across European and global public health networks. Crucially, leading SME partners will expand business portfolios into a well-defined market, progress novel intellectual property and access several in-licensing opportunities. ANGIOPREDICT uniquely unites world-class molecular diagnostic biomarker discovery SMEs with leading clinical and academic entities to identify a new generation of individualized methods for predicting response to combination bvz therapy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- medical and health sciences clinical medicine oncology colorectal cancer
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-HEALTH-2011-two-stage
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
2 DUBLIN
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.